By Markus Aarnio : Illumina ( ILMN ) develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. (click to enlarge) Insider
Gallagher : A trailblazing pioneer, Affymetrix ( AFFY ) got off largely under-the ..... came public with its IPO in June 1996. AFFX "blasted-off" like a rocket in the ..... clinical research, I was intrigued at Affymetrix 's technology and its potential, and
Affymetrix ( AFFX ): Q1 EPS of $0.01 beats by $0.01 . Revenue of $77.9M misses by $2.06M . ( PR ) Post your comment!
(Reuters) - Affymetrix Inc estimated third-quarter revenue that was below Wall Street expectations, as tightening academic funding worldwide reduced sales at its gene expression and eBioscience...
By Kapitall : Over 1,100 companies are reporting their third-quarter earnings next week – do you have a watch list prepared? For ideas, we ran a screen on next week’s reporting companies from the tech sector that have been seeing bullish sentiment from short sellers, with significant decreases in
We are no longer providing equity research on Affymetrix AFFX . We provide broad coverage of more than 1,700 companies across more than 140 industries and adjust our coverage as necessary based on client demand and investor interest.
(Reuters) - Shares of Affymetrix Inc fell about 20 percent on Thursday, a day after the genetic analysis products maker reported preliminary second-quarter revenue below market expectations.
Affymetrix has faced pricing pressure on its consumables ..... a device in the sequencing market, Affymetrix has missed out on a high-growth research ..... manufacturing difficulties may have harmed Affymetrix 's reputation and prompted customers
2.05 beats by $0.21 . Revenue of $3.4B (+4% Y/Y) beats by $0.07B . Shares -5.1% AH. ( PR ) Affymetrix ( AFFX ): Q4 EPS of $0.06 beats by $0.04 . Revenue of $84.9M (-4.4% Y/Y) in-line. Shares +2.4